ImpriMed offers precision medicine techniques to veterinary oncologists, helping them identify appropriate anticancer drugs by analyzing live cancer cells of pet patients before treatment. By building a patient-derived database for pet cancer treatment, ImpriMed aims to translate this knowledge into human cancer care. The company's personalized drug testing service enables doctors to make data-driven predictions of response success in each individual patient, allowing for informed decisions on treatment regimens. Founded in 2017 and based in Palo Alto, California, ImpriMed is dedicated to improving cancer treatment outcomes for pets and humans alike.